Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.
Justin Gainor, MD
Advertisement
Articles by Justin Gainor, MD
Justin F. Gainor, MD, director of targeted immunotherapy, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses clinical activity and tolerability of BLU-667 in patients with advanced RET-fusion+ non-small cell lung cancer (NSCLC).
Advertisement
Latest Updated Articles
Dr. Gainor on Potential With BLU-667 in RET+ NSCLCJune 19th 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts Third RP1 BLA Resubmission With Nivolumab in Advanced Melanoma
2
MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes
3
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
4
Analysis Identifies Potential Response, Resistance Biomarkers to Mogamulizumab in R/R Mycosis Fungoides/Sézary Syndrome
5